CLINICAL TRIALS PROFILE FOR POTELIGEO
✉ Email this page to a colleague
All Clinical Trials for POTELIGEO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04848064 ↗ | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | Recruiting | John Reneau | Phase 1 | 2021-11-01 | This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for POTELIGEO
Condition Name
| Condition Name for POTELIGEO | |
| Intervention | Trials |
| Recurrent Adult T-Cell Leukemia/Lymphoma | 1 |
| Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 1 |
| Refractory Adult T-Cell Leukemia/Lymphoma | 1 |
| Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for POTELIGEO
Trials by Country
Clinical Trial Progress for POTELIGEO
Clinical Trial Phase
Clinical Trial Sponsors for POTELIGEO
Sponsor Name
